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Abstract
Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease affecting multiple organ 
systems and characterized by autoantibody formation to nuclear components. Although genetic 
variation within the major histocompatibility complex (MHC) is associated with SLE, its role in 
the development of clinical manifestations and autoantibody production is not well defined. We 
conducted a meta-analysis of four independent European SLE case collections for associations 
between SLE sub-phenotypes and MHC single-nucleotide polymorphism genotypes, human 
leukocyte antigen (HLA) alleles and variant HLA amino acids. Of the 11 American College of 
Rheumatology criteria and 7 autoantibody sub-phenotypes examined, anti-Ro/SSA and anti-
La/SSB antibody subsets exhibited the highest number and most statistically significant 
associations. HLA-DRB1*03:01 was significantly associated with both sub-phenotypes. We found 
evidence of associations independent of MHC class II variants in the anti-Ro subset alone. 
Conditional analyses showed that anti-Ro and anti-La subsets are independently associated with 
HLA-DRB1*0301, and that the HLA-DRB1*03:01 association with SLE is largely but not 
completely driven by the association of this allele with these sub-phenotypes. Our results provide 
strong evidence for a multilevel risk model for HLA-DRB1*03:01 in SLE, where the association 
with anti-Ro and anti-La antibody-positive SLE is much stronger than SLE without these 
autoantibodies.
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INTRODUCTION
Systemic lupus erythematosus (SLE; OMIM 152700) is a complex autoimmune disease that 
can affect multiple organ systems. Processes involving both the innate and adaptive immune 
systems contribute to its development.1 The disease is clinically heterogeneous, and affected 
individuals only need 4 out of 11 of the American College of Rheumatology (ACR) criteria 
to be classified as having SLE. Although patients may differ in their clinical manifestations, 
patients do share a propensity to develop autoantibodies directed against nucleic acids and 
associated nuclear and cellular proteins.
There is overwhelming evidence of a genetic component to SLE risk with higher 
concordance rates observed between monozygotic twins (20–40%) compared with dizygotic 
twins (2–5%).2 The familial aggregation for SLE (sibling risk ratio, λs = 8–29)2,3 is higher 
than other autoimmune diseases, and the estimate of heritability is approximately 66%.4 
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Genetic association studies of SLE have been successful in identifying multiple loci.5–11 
However, relatively few studies have investigated the genetic association with specific SLE 
sub-phenotypes.12–15 These studies focused mainly on major histocompatibility complex 
(MHC) class II genes, and found evidence that class II alleles such as HLA-DRB1*03:01 are 
associated with auto-antibody production.13 Our study substantially expands this work by 
not only analysing imputed classical human leukocyte antigen (HLA) alleles, but also 
examining variant HLA amino-acid positions in conjunction with single-nucleotide 
polymorphism (SNP) genotypes across the extended MHC region (chromosome 6: 26–34 
Mb). Our aim was to discover genetic loci within the MHC region that are associated with 
specific clinical and/or immunological manifestations within SLE cases and hence to find 
evidence of genetic variants that may drive specific forms of the disease. For complex 
heterogeneous diseases such as SLE, comprehensive sub-phenotype studies are critical in 
order to understand how previously identified genetic associations contribute to disease 
pathogenesis and specific disease manifestations.
RESULTS
Study sample
For this study, we collected genetic and sub-phenotype data from 3070 SLE cases of 
European descent characterized in four genetic association studies of SLE. These SLE cases 
were previously examined in a large meta-analysis that examined the association between 
MHC genetic variation and SLE susceptibility.16 Table 1 describes the genotyping platform, 
number of genotyped MHC SNPs, and sample size of each case collection in the study. 
Given the strong genetic associations observed with anti-Ro/SSA and anti-La/SSB 
autoantibody production described below, Table 1 also provides the frequency of these 
antibodies for each case collection. Genetic (SNP) imputation was performed previously16 
for each case collection, resulting in a total of 7119 SNPs common between the four 
collections. In addition, classical HLA class I and II alleles as well as their corresponding 
variant amino acids (AAs, see Materials and Methods) were imputed and analysed.
Selection of sub-phenotypes for analysis
We examined the 11 ACR classification criteria17 and 7 SLE-related autoantibodies (anti-
double-stranded DNA, anti-Sm, anti-RNP, anti-Ro/SSA, anti-La/SSB, anti-cardiolipin IgG 
and anti-cardiolipin IgM) as candidate sub-phenotypes for this study. Single-marker 
associations for each candidate sub-phenotype with all variants were assessed using logistic 
regression adjusted for population substructure and case collection (Supplementary Table 1). 
We analysed 7656 variants in total (7119 SNPs, 199 HLA alleles and 338 HLA amino-acid 
positions (see methods)). The specific sub-phenotypes comprising anti-Ro and anti-La 
antibodies demonstrated by far the most associations: 1635 and 1828 variants, respectively, 
at P<0.00001. For all other sub-phenotypes, there were fewer than 30 variants that were 
significant at this level. Thus, we targeted anti-Ro and anti-La antibody subsets for detailed 
investigation as they have the strongest evidence for a genetic aetiology.
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Anti-Ro antibody sub-phenotype
Stepwise conditional analysis—The most associated marker (in terms of P-value as a 
single marker) was the class III SNP rs3129962 in BTNL2 (P =9.47 × 10 −27; odds ratio 
(OR) = 2.44, 95% confidence interval (CI) =2.08–2.94; Table 2A). This marker is in linkage 
disequilibrium (LD) with HLA-DRB1*03:01 (R2 =0.84, D′ =0.99). When conditioning on 
this SNP as a covariate in forward stepwise regression, the next most associated marker was 
the class II SNP, rs9271731, between HLA-DRB1 and HLA-DQA1 (P = 9.56 × 10 −07; OR = 
1.54, 95% CI =1.30–1.85). This SNP is in LD with HLA-DRB1*15:01 (R2 =0.72, D′ = 1). 
When using rs9271731 as an additional covariate, one further association signal was 
detected at the class II SNP, rs3957146, between HLA-DQB1 and HLA-DQA2 (P =5.70 × 
10 −06; OR =0.52, 95% CI =0.39–0.69). Of note, the effect sizes (ORs) and P-values that we 
present here are estimated from the multivariate models returned by stepwise regression 
(columns 2–3 in Table 2). The association results for a given variant from single marker 
analyses can be seen in the last two columns of Table 2.
The most associated amino acid (AA) was at position 77 in HLA-DRB1 with the common 
AA threonine having a protective effect (P =2.72 × 10−13; OR =0.49; 95% CI =0.41–0.60). 
HLA-DRB1*03:01 and HLA-DRB1*03:02 encode the single alternative AA, asparagine, (R2 
=1). HLA-DRB1*03:02 is not significantly associated with this sub-phenotype (P =0.37) 
possibly because of this allele being rare (frequency of 0.01% in our data). We cannot be 
certain that this lack of association applies to the general population and this needs to be 
investigated to address this uncertainty. All other HLA-DRB1 alleles code for threonine. The 
single marker P-value for this AA was very close to that of the most strongly associated 
SNP (see last column in Table 2). Therefore, we ran a stepwise regression starting from this 
marker. When conditioning on this AA, the next most associated marker was the class II 
SNP, rs9271731, between HLA-DRB1 and HLA-DQA1 (P =4.5 × 10−08; OR = 1.63, 95% CI 
=1.37–1.95). When using rs9271731 as an additional covariate, one further association 
signal was detected at the class III SNP, rs3130781, in DPCR1 (P =1.76 × 10−05; OR =1.44, 
95% CI =1.22–1.71). The SNP rs3130781 is in LD with HLA-DRB1*03:01 (R2 = 0.29, D′ 
=0.64) and HLA-B*08:01 (R2 =0.29, D′ =0.72). One final association signal was detected at 
HLA-DQB1*03:02 (P =2.49 × 10−05; OR =0.56, 95% CI = 0.42–0.73). The results from this 
analysis can be seen in Table 2B.
Owing to the correlation between the most associated SNPs with known associated HLA-
DRB1 alleles (rs3129962 tags HLA-DRB1*03:01/Thr77 in DRB1 (R2 =0.84); rs9271731 
tags HLA-DRB1*15:01), we performed stepwise regression conditioning on these HLA 
alleles as covariates. When conditioning on HLA-DRB1*03:01 and HLA-DRB1*15:01, the 
next most associated marker (rs9275582) was in class II between HLA-DQB1-HLA-DQA2 
(P =2.99 × 10−06; OR =0.61; 95% CI =0.5–0.76). The most significant HLA allele was 
HLA-DQB1*03:02, which is in LD with rs9275582 (R2 =0.29, D′ =0.80). These two sets of 
results can be seen in Tables 2C and 2D. We note that HLA-DQB1*03:02 is in LD (R2 = 
0.58) with rs3957146 (the third associated SNP in the first stepwise regression presented in 
Table 2).
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A simple stepwise regression analysis including only AA variants indicated associations 
with Thr77, Leu67 and Gln96 in HLA-DRB1 (Table 2E). The HLA-DRB1 AA glutamine at 
position 96 is in LD with HLA-DRB1*15:01 (R2 =0.82, D′ =1.00).
Model choice using the bayesian information criterion (BIC)—Owing to the 
extended LD, an analysis of the MHC using stepwise regression to find evidence for 
multiple independently associated variants can lead to many models depending on the first 
marker conditioned on (used as a covariate for further association analysis). This was 
discussed previously16 and here we also used the BIC as an aid to model choice; the lower 
the BIC, the better fit the model is to the data (see methods). In our analysis of sub-
phenotype data, there was not much difference between models A, C, D and E in Table 2 in 
terms of the BIC, which represents the relative belief in a model given the data. However, 
model B, which began the forward stepwise regression with threonine at position 77 in HLA-
DRB1, had the lowest BIC. This model does have one more term than the other four models. 
Our extended model search (see methods) did not result in a model with a lower BIC.
Haplotype analysis—There are two main extended MHC haplotypes associated with 
SLE in northern Europeans that contain the class II alleles HLA-DRB1*03:01 and HLA-
DRB1*15:01.18 These extended haplotypes are comprised of the following HLA alleles: 
HLA-A*03:01—HLA-B*07:02—HLA-C*07:02—HLA-DRB1*15:01—HLA-D QA1*01:02
—HLA-DQB1*06:02 and HLA-A*01:01—HLA-B*08:01—HLA-C*07:01—HLA-
DRB1*03:01—HLA-DQA1*05:01—HLA-DQB1*02:01. We tested for association of these 
extended haplotypes with anti-Ro antibody status with the hypothesis that the association 
signals at HLA-DRB1*03:01 and HLA-DRB1*15:01 are independent of these haplotypes. 
We observed significant effects for both haplotypes (HLA-DRB1*03:01: P =1.02 × 10−12, 
OR =2.17; HLA-DRB1*15:01: P =0.02, OR =1.71). We found evidence that HLA-
DRB1*03:01 is associated independently of the HLA-B*08:01-DRB1*03:01 haplotypic 
background (P = 3.05 × 10−07), whereas we fail to find evidence that HLA-DRB1*15:01 (P 
= 0.17) is independent of the HLA-B*07:02-DRB1*15:01 haplotype.
Anti-La antibody subphenotype
Stepwise conditional analysis—The most strongly associated marker with the anti-La 
autoantibody sub-phenotype was the SNP rs2894254, in the class III region (P =3.40 × 
10−30; OR = 3.38, 95% CI =2.74–4.16). This SNP is in LD (R2 =0.84, D′ = 0.99) with HLA-
DRB1*03:01. We do not find further associations when conditioning on this SNP as a 
covariate. However, if we condition on HLA-DRB1*03:01, we find a further association 
with rs9268832, located between HLA-DRA and HLA-DRB5 in class II (P =6.53 × 10−06; 
OR =1.64; 95% CI =1.32–2.04). Results from these two models can be seen in Table 3. The 
HLA-DRB1 AA threonine at position 77 was observed to have a protective effect, consistent 
with the anti-Ro analyses. However, this AA was not the most associated marker (P =2.4 × 
10−28). Conditioning on Thr77, we find an additional association with rs2227139, located in 
HLA-DRA in class II (P =6.47 × 10−06; OR = 1.64; 95% CI =1.32–2.04). The SNP, 
rs2227139, is in LD with rs9268832 (R2 = 0.91, D′ =0.96).
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Model choice using the BIC—As with the analysis of anti-Ro, we used the BIC as an 
aid to model comparison. The model including AA variation has the lowest BIC (model C in 
Table 3) but is only slightly lower than the model conditioning on HLA-DRB1*03:01. 
Therefore, we cannot choose between the AA and the HLA allele as the best explanation for 
the data; however, conditional on either of these we find an independent association in class 
II. Both of these models have a lower BIC than model A, which only has the single most 
associated SNP (rs2894254). These data therefore favour two independent associations in 
class II, one of which is most likely HLA-DRB1*03:01 or the HLA-DRB1 AA threonine at 
position 77. Our extended model search (see methods) returned the same models as in Table 
3.
Haplotype analysis—We observed significant effects for the HLA-DRB1*03:01 
haplotype but not the HLA-DRB1*15:01 haplotype with anti-La antibody status (HLA-
DRB1*03:01: P =1.19 × 10 −16, OR =3.12; HLA-DRB1*15:01: P =0.63). We found 
evidence that HLA-DRB1*03:01 is associated independently of the HLA-B*08:01-
DRB1*03:01 haplotype (P = 6.42 × 10 −13).
Independence of anti-Ro and anti-La autoantibody associations with HLA-DRB1*03:01
Thus far, we have observed strong evidence of association between HLA-DRB1*03:01 and 
both anti-Ro and anti-La autoanti-body subsets. As these two phenotypes are correlated (R2 
=0.27), we performed conditional analyses to determine whether the associations for each 
sub-phenotype were independent of each other. We performed logistic regression analysis 
with each sub-phenotype as an outcome and the other sub-phenotype as a covariate. Table 4 
displays the sample sizes and HLA-DRB1*03:01 frequencies for these case only analyses.
When conditioning on anti-La as a covariate, HLA-DRB1*03:01 continues to be strongly 
associated with anti-Ro antibody status (P = 1.23 × 10 −07, OR =1.60 95% CI =1.02–2.54). 
Also, when conditioning on anti-Ro, HLA-DRB1*03:01 continues to be strongly associated 
with anti-La antibody status (P =1.66 × 10 −12, OR =2.57 95% CI =1.98–3.34). To assess 
the robustness of these conditional regression results, we examined the anti-Ro association 
in only anti-La-negative cases and found that HLA-DRB1*03:01 was still strongly 
associated with anti-Ro (P =6.79 × 10 −07, OR =1.58 95% CI =1.32–1.89). In anti-La 
antibody-positive SLE cases, HLA-DRB1*03:01 is weakly associated with anti-Ro (P = 
0.055, OR = 2.37 95% CI =0.98–5.74). We performed the same analyses for the anti-La 
antibody subset, stratifying on the anti-Ro phenotype. In anti-Ro-positive SLE cases, HLA-
DRB1*03:01 is strongly associated with anti-La (P =6.18 × 10 −12, OR =2.81 95% CI 
=2.09–3.77). Among anti-Ro-negative SLE cases, HLA-DRB1*03:01 is weakly associated 
with anti-La (P =0.06, OR =1.96 95% CI =0.97–3.73). Therefore, we conclude that the 
association signal for HLA-DRB1*03:01 with anti-La is not due to this sub-phenotype’s 
correlation with anti-Ro, and vice-versa.
The HLA-DRB1*03:01 association with SLE susceptibility is independent of the association 
with anti-Ro and anti-La antibody subsets
We have provided strong evidence for the association between HLA-DRB1*03:01 and both 
anti-Ro and anti-La antibody subsets. This HLA-DRB1 allele has been consistently and 
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strongly associated with SLE susceptibility in European populations,16 and this is confirmed 
in our current data (P =3.38 × 10−49; OR =1.86 95% CI =1.71–2.02). However, the 
association of HLA-DRB1*03:01 with anti-Ro/anti-La antibody subsets and SLE 
susceptibility may not be independent—the DRB1*03:01 association with SLE may be 
purely secondary to its association with anti-Ro and anti-La antibody status.
If the association between HLA-DRB1*03:01 and SLE status is not driven entirely by sub-
phenotype then one could hypothesize a three-level model of disease type (unaffected; sub-
phenotype-negative case; sub-phenotype-positive case) based on increasing HLA-
DRB1*03:01 frequency. Figure 1 plots the change in HLA-DRB1*03:01 dosage over levels 
of disease; the average dosage appears to increase over all three levels. Therefore, we 
examined (see methods) the hypothesis that the HLA-DRB1*03:01 association with anti-Ro 
and anti-La antibody sub-phenotypes explains the association of DRB1*03:01 with SLE in 
general. We also tested whether the risk was additive over the three levels of disease.
Anti-Ro antibody sub-phenotype
We found a significant difference in HLA-DRB1*03:01 dosage between healthy controls and 
anti-Ro antibody negative cases (P = 1.97 × 10 −14). The estimated change in dosage was 
0.1 (95% CI =0.08–0.13), equivalent to a change in allele frequency of 0.05 (95% CI =0.04–
0.06).
We also found a significant increase in dosage between anti-Ro-negative cases and anti-Ro 
positive cases (P =2.97 × 10−33). The estimated change in dosage (see Table 5) is 0.27 (95% 
CI =0.22–0.31), equivalent to a change in frequency of 0.13 (95% CI = 0.11–0.16).
We found evidence against the hypothesis that the increase in dosage is additive over the 
three disease levels (P =0.008). Our final test against the additive model implies that the 
difference in HLA-DRB1*03:01 dosage between anti-Ro(−)/anti-Ro( +) status (increase of 
0.27) in the cases is more than double that of the difference between cases and healthy 
controls (increase of 0.10).
Anti-La antibody subphenotype
We found a significant difference in HLA-DRB1*03:01 dosage between healthy controls and 
anti-La-negative cases (P =3.57 × 10 −25). The estimated change (see Table 5) in dosage is 
0.13 (95% CI = 0.11–0.15), equivalent to a change in frequency of 0.06 (95% CI =0.05–
0.08).
We also found a significant increase in dosage between anti-La-negative and anti-La-
positive cases (P = 2.45 × 10 −39). The estimated change in dosage (see Table 5) is 0.41 
(95% CI =0.35–0.47), equivalent to a change in frequency of 0.21 (95% CI =0.18–0.24).
We found evidence against the hypothesis that the increase in dosage is additive over the 
three disease levels (P =1.5 × 10 −04). Table 5 displays the effect sizes and P-values for this 
analysis. Our final test against the additive model implies that the difference in HLA-
DRB1*03:01 dosage between anti-La( −)/anti-La( + ) status (increase of 0.41) in the cases is 
more than triple that of the difference between cases and healthy controls (increase of 0.13).
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Double positive and double negative anti-Ro and anti-La antibody sub-phenotypes
Our study was large enough to determine whether the frequency of HLA-DRB1*03:01 
differs between SLE cases who are double negative for anti-Ro and anti-La antibodies (N 
=1781) and healthy controls (N =9782). It is known that these antibodies are present in 
approximately 2% of the healthy population; however, we do not have this phenotype data 
for the controls. The following results therefore assume that all controls are negative for 
antinuclear antibodies. We found a significant association of HLA-DRB1*03:01 with the 
double negative SLE cases/healthy controls status (OR =1.49, 95% CI =1.35–1.65; P = 2.23 
× 10 −14). Further analysis demonstrated a stronger association with the double positive (n 
=259)/double negative SLE case status (OR =3.71, 95% CI = 2.97–4.64; P =2.00 × 10 −16). 
To test whether these two odds ratios differ, we ran the same analysis for a three-stage risk 
model as we did for anti-Ro and anti-La antibody subsets separately (see above, Table 5 
results). We found very strong evidence against the hypothesis that the increase in dosage is 
additive over the three disease levels (P = 6.65 × 10 −06). The non-additive effect leads to a 
very large odds ratio between double positive SLE cases and healthy controls, which we 
found to be 5.27 (95% CI = 4.31–6.44; P =3.14 × 10 −59; Figure 1).
DISCUSSION
Our results confirm, in the largest SLE sub-phenotype genetic association study to date, that 
the often replicated genetic association at HLA-DRB1*03:01 does not just influence SLE 
susceptibility but is also associated with anti-Ro and anti-La autoantibody production. For 
the first time, we have shown that HLA-DRB1*03:01 is associated with SLE per se, 
independent of anti-Ro and anti-La antibody subsets. These data implicate HLA-
DRB1*03:01 and variants in LD with it in the predisposition to anti-Ro and anti-La 
autoantibody production as well as processes outside of this manifestation.
We do not find conclusive evidence that variant HLA AAs explain the majority of the MHC 
association signal in anti-Ro and anti-La autoantibody subsets in SLE. This is largely due to 
the confounding effects of extended LD displayed by the associated DRB1*03:01 and to a 
lesser extent, the DRB1*15:01 haplotypes in our study cohorts. These results contrast with 
those of a recent study in anti-CCP-positive rheumatoid arthritis, where five HLA AA 
variants were suggested to largely explain the MHC association with disease status.19 In this 
case, the disease-associated variants generally reside on a diversity of haplotypes. Studies in 
other autoimmune/inflammatory diseases have either not shown robust association signals 
with variant HLA AA data or like the present study have shown association with AAs in 
strong LD with previously associated HLA alleles. It may be that HLA amino association 
signals are more complex than the single-variant testing method we and others have used.
Limitations of the present study include the heterogeneity in autoantibody testing procedures 
and sub-phenotype data collection between the four studies. As a result, data were tabulated 
and analysed in an essentially binary format (that is, individual cases were classified as 
positive, negative or missing for each trait), to allow meta-analysis. However, in so doing, a 
degree of noise is inevitable, which would reduce our power to detect true association 
signals particularly in the less common sub-phenotypes. We were also limited by the 
imputation required to analyse a consistent set of SNPs across studies and the reliance on 
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HLA imputation. In addition, we are constrained in our conclusions on differences in results 
for anti-Ro and anti-La antibody subsets given the much smaller sample size available for 
the anti-La phenotype. Thus, we have confined some of our analyses to the most robust 
association; that of HLA-DRB1*03:01 with both anti-Ro and anti-La antibody sub-
phenotypes. We must also allow for the possibility that associations with HLA-DRB1*03:01 
could exist with other SLE subsets that overlap with anti-Ro/La, but have not been detected 
in our study. This highlights the need for extension of this work to other cohorts with sub-
phenotype data in order to increase sample size and power across as wide a range of 
phenotypes as possible.
In both anti-Ro and anti-La sub-phenotypes, we find evidence of secondary independent 
associations in the class II region of the MHC after conditioning on HLA-DRB1*03:01, and 
we find additional signals in class II and class III for anti-Ro. We have shown that the 
association of HLA-DRB1*03:01 with anti-Ro antibody status is independent of the 
association with anti-La and vice-versa. We have also shown that the association between 
SLE case/healthy control and HLA-DRB1*03:01 is not purely due to the association with 
anti-Ro and anti-La antibody sub-phenotypes. This implies a three-level model of risk for 
increasing dosage of HLA-DRB1*03:01, where the frequency of this allele is higher in anti-
Ro-negative cases than in healthy controls and higher still in anti-Ro-positive cases than 
anti-Ro-negative cases. The same is true for anti-La. In fact, we find very strong evidence 
that the HLA-DRB1*03:01 risk of anti-Ro/anti-La double positive within SLE patients is 
much greater than the risk of anti-Ro/anti-La double negative (other lupus phenotypes 
without these anti-bodies present) in the general population. We can conclude that the 
association of HLA-DRB1*03:01 with SLE is driven to a large extent but not entirely by 
anti-Ro and anti-La auto-antibody sub-phenotypes.
Although we do find evidence of an independent class III association with anti-Ro, there is 
some uncertainty. We find a significant association with the class III SNP rs3130781 
conditional on the AA Thr77-DRB1. However, when conditioning on the markers in model 
C in Table 2 (HLA-DRB1*03:01 +HLA-DRB1*15:01 + rs9275582; BIC =2829.8) in a 
forward stepwise regression, the association with rs3130781 is not significant (P = 4.2 × 
10 −05). This is also the case for model D in Table 2 (HLA-DRB1*03:01 + HLA-
DRB1*15:01 +HLA-DQB*03:02; BIC =2829.6). So conditional on HLA-DRB1*03:01 and 
HLA-DRB1*15:01, we find an independent association in class II but not class III. However, 
we did consider conditioning on HLA-DRB1*03:01 alone, where a stepwise regression 
returned a class II SNP (rs9271731; R2 with HLA-DRB1*15:01 =0.72) and the class III SNP 
rs3130781. This model has a BIC =2929.00. Hence, there is uncertainty as to whether there 
is an independent class III effect when conditioning on HLA-DRB1*03:01; all three models 
fit the data equally well (not much difference in the BIC). Nevertheless, the best model in 
Table 2 does suggest that there is an independent class III effect conditional on the class II 
AA Thr77-DRB1. This model has a much lower BIC than any others. There is some 
evidence, therefore, of a class III association with anti-Ro; however, we believe that more 
data, and ideally across diverse populations (to help remove effects due to LD), are required 
to be more definitive about this.
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The results of the present study while enlightening are confounded by the strong and 
extended LD present on the principally associated HLA-DRB1*03:01 and HLA-DRB1*15:01 
haplotypes. Complementary studies in accurately phenotyped southern European and non-
European SLE cohorts, which show haplotypic diversity at the MHC, will allow refinement 
of the sub-phenotype association signals found in the predominantly northern European 
populations studied thus far.20 These efforts may still yield association intervals that harbour 
several genes/variants. Therefore, future work will inevitably require re-sequencing, 
transcriptomic and epigenetic studies in order to tease out these complex association signals.
MATERIALS AND METHODS
Study design
This study is a meta-analysis of four studies taken from work described in a previous 
paper.16 We only included four of the six previous studies in this work as sub-phenotype 
data were not available from the other two studies (named ‘Affy500K’ and ‘Affy100K’ in 
the previous paper). We refer to the previous meta-analysis of SLE case–control data as the 
‘parent study’ in this work. The number of SLE cases and controls in this paper for the four 
included studies are the same as in the parent study, and quality control (QC) procedures for 
these data are described in full in the previous paper, including tests for relatedness and 
adjustments for population structure. We include some QC descriptions below for clarity in 
this paper.
QC and imputation
SNPs—We only analysed SNPs that passed QC in our previous paper,16 which utilized 
these data: 90% genotyping for all subjects and SNPs, minor allele frequency >0.01 and 
Hardy–Weinberg equilibrium (false discovery rate of 0.05).
HLA imputation—We imputed HLA genotypes using HLA*IMP V2.21 Only genotyped 
SNPs in each case collection were used for this imputation. We used posterior probabilities 
of HLA genotypes, rather than most likely genotypes, in order to allow for uncertainty in 
imputation. From these probabilities, we calculated dosages for each allele (expected 
number of alleles 0<x<2). We had HLA-DRB1 typed data in two studies: the ‘Illumina 
Combined MHC panel’ study (N =1608) and the ‘Illumina Custom panel’ study (N = 605). 
This allowed for assessment of accuracy, which for the two main reported positive 
associations in this paper were as follows: for HLA-DRB1*03:01, we achieved sensitivity of 
0.992/0.999 and specificity of 0.995/0.993 for the Illumina Combined MHC panel and 
Illumina Custom panel’ respectively. For HLA-DRB1*15:01, we achieved sensitivity of 
0.980/0.992 and specificity of 0.996/0.997.
AA translation
AA sequences for each HLA allele were extracted from the European Bioinformatics 
Institute HLA database (http://www.ebi.ac.uk/ipd/imgt/hla/). HLA allele dosages were 
converted to AA dosages at each position; the dosage for a particular amino acid ‘A’ at 
position ‘p’ would be the sum of HLA alleles’ dosage that coded for amino acid ‘A’ at 
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position ‘p’. The total dosage for each position is therefore equal to 2 and this total is split 
between each possible AA at the position.
We had data at 338 AA positions that had variable AAs (HLA-A =67, HLA-B = 75, HLA-C 
=71, HLA-DPB1 = 21, HLA-DQA1 = 41, HLA-DQB1 =61, HLA-DRB1 = 52). Owing to 
multiple possible AAs at each position, we actually had 1255 possible position/AA variants 
in total.
Adjustment for population structure—We analysed the data with the statistical 
computing language R22 using logistic regression. All analyses were adjusted for ancestry 
utilizing the first principal component (PC) or percentage of northern European ancestry, as 
previously described16 and included a covariate for project. As the PCs were computed 
specifically for each case collection, we also included interaction terms between projects and 
ancestry to allow for different effect sizes in the adjustment for population structure.
Single-marker analysis of candidate sub-phenotypes and analysis of SLE as a 
simple disease outcome—We examined the 11 ACR criteria17 and presence of 7 SLE-
related auto-antibodies (anti-Ro/SSA, anti-La/SSB, anti-double-stranded DNA, anti-RNP, 
anti-Sm and anticardiolipin IgG and IgM) as candidate sub-phenotypes for detailed analysis. 
To determine which sub-phenotypes were most strongly influenced by genetic variation in 
the MHC, we tested each sub-phenotype for association with all variants (SNPs, HLA alleles 
and HLA AAs) in single-variant association tests using logistic regression adjusted for 
population substructure and case collection. We also tested the association between markers 
and SLE as a simple disease outcome for the four studies considered here. Results for 
association with HLA-DRB1*03:01 are discussed in the beginning of the section titled ‘The 
HLA-DRB1*03:01 association with SLE susceptibility is independent of the association with 
anti-Ro and anti-La antibody subsets’.
Conditional association analysis of anti-Ro and anti-La—Owing to numerous 
single-marker associations within the extended LD of the MHC, we used conditional 
analyses to narrow these associations to those with the best evidence for strength and 
independence. All analyses utilized logistic regression with ancestry and project covariates 
(see above) and were halted when the evidence for association with a new term was P>3 × 
10 −05. We performed classic forward stepwise regression, conditioning on the top variant to 
find the second variant, and so on.
A simple forward stepwise approach can lead to over-fitting (selecting many correlated 
markers) and the results may be misleading because of selected markers potentially tagging 
two or more independently associated markers.16 Therefore, we also performed a model 
search using the BIC16 as the inclusion metric in a stepwise regression using the R22 ‘step()’ 
function, first starting with no prior model (other than covariates above) and also starting 
from HLA-DRB1*03:01 and HLA-DRB1*15:01 as initial model terms. Although BIC 
optimization was used to select model terms, we terminated the selection when it would 
result in a term with P>3 × 10−5. The BIC23,24 is a penalized likelihood model choice 
criterion similar to the Akaike Information Criterion24 except there is a stronger penalty for 
additional model parameters that increases with sample size. The BIC is therefore more 
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conservative and favours smaller models than the Akaike Information Criterion. As with the 
Akaike Information Criterion, the smaller the BIC the better the model is judged to fit the 
data.
Haplotype analysis of anti-Ro and anti-La—Given the high degree of correlation 
between the associated variants identified from the model searches described above, we 
conducted a haplotype analysis of these variants using PLINK25 using the best-guess 
genotypes estimated from HLA*IMP2. We used PLINK to phase haplotypes and perform 
multivariate logistic regression where terms are haplotypes rather than individual variants, 
optionally controlling for individual variants or haplotypes.
Multiple testing—In the MHC, a Bonferroni adjustment for multiple testing is 
inappropriate because of the extensive LD and hence correlated variants. In order to 
determine the number of independent variants, we performed a PC analysis of all SNPs. In 
our data, we found that 374 PCs had eigenvalues >1 and these PCs explained 96% of the 
variance. Thus, we used a multiple-testing threshold of P<0.01/374 = 3 × 10 −5.
Testing for independence between the SLE association and sub-phenotype 
association with HLA-DRB1*03:01—We fitted a linear regression model with dosage 
for HLA-DRB1*03:01 as the outcome and both case/control status and sub-phenotype status 
as explanatory variables. We therefore tested each effect conditional on the other. A 
significant association for case/control status conditional on sub-phenotype implies that we 
reject the hypothesis that sub-phenotype is solely driving the case/control association. This 
is equivalent to setting the three-level status as a factor in the regression in terms of model 
fit. But rather than obtaining an estimate of dosage change between healthy controls and 
sub-phenotype positive as we would in a three-level factor (where the baseline is healthy 
control), we get an estimate of change between sub-phenotype positive and sub-phenotype 
negative. In both models, we also get an estimate of change between healthy controls and 
sub-phenotype negative.
Furthermore, we tested the hypothesis that the increase in dosage is additive over the three 
disease levels (Healthy-Control Case sub-phenotype negative/Case sub-phenotype positive). 
This is achieved by fitting a model with an additive effect for dosage over the three 
phenotype levels. This additive model is nested within our model used to test independence 
of sub-phenotype association with SLE-case/healthy control, so we performed a likelihood 
ratio test. A rejection of this additive model, in favour of the three-level factor model 
(described in the previous paragraph), is evidence that the change in dosage over sub-
phenotype within cases is different than the change in dosage between healthy controls and 
SLE without the sub-phenotype.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
HLA-DRB1*03:01 dosage (average number of alleles observed) over levels of disease (a): 
(healthy controls/anti-Ro( −)/anti-Ro( +)); (b): (healthy controls/anti-La( −)/anti-La( +)); (c) 
(healthy controls/anti-Ro( −) AND anti-La( −)/anti-Ro( +) AND anti-La( +)/). Average 
dosage is represented by a square, whereas upper and lower 95% confidence intervals are 
represented by ‘ −’. Note that dosage ranges from 0 to 2 for each subject and so to convert to 
allele frequency you must divide by 2. All three plots have been truncated at 1.
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Table 1
Individual studies with number of genotyped SNPs, number of SLE cases and sample sizes for anti-Ro/La 
within cases
Study case collection N genotyped MHC SNPsa N casesb Sample sizes (+/−/missing)
Illumina HumanHap5506 2380 1123 Anti-Ro: 319/796/8
anti-La: 137/978/8
Illumina HumanHap3175 1522 398 Anti-Ro: 36/107/225
anti-La: 17/126/255
Illumina Combined MHC panel26 2360 917 Anti-Ro:158/454/305
anti-La:79/531/307
Illumina custom panel27 1230 632 Anti-Ro: 168/446/18
anti-La: 48/565/19
Abbreviations: MHC, major histocompatibility complex; SLE, systemic lupus erythematosus; SNP, single-nucleotide polymorphism. The last 
column denotes the number of SLE cases who were positive, negative or had missing data for each sub-phenotype.
aNumber of SNPs on the genotyping platform located on chromosome 6 between 26 000 and 34 000 kb.
bSee original paper16 for a description of SLE case recruitment.
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Table 4
Allele frequencies for HLA-DRB1*03:01 in case only association analysis of anti-Ro and anti-LA when 
conditioning on the status of each sub-phenotype
Status Anti-La( +), N Anti-La( −), N
Anti-Ro( +) 0.41 (259) 0.26 (418)
Anti-Ro( −) 0.28 (22) 0.18 (1781)
Frequencies for the HLA-DRB1*03:01 allele are shown with the sample sizes in brackets.
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Table 5
Multi-level model for HLA-DRB1*03:01 dosage over phenotype
Phenotype Effect (change in dosage) 95% CI P-value
(A) Results for anti-Ro
 Anti-Ro( −)/control 0.10 0.08–0.13 1.97 × 10 −14
 Anti-Ro( +)/anti-Ro(−) 0.27 0.22–0.31 2.97 × 10 −33
(B) Results for anti-La
 Anti-La( −)/control 0.13 0.11–0.15 3.57 × 10 −25
 Anti-La( +)/anti-La( −) 0.41 0.35–0.47 2.45 × 10 −39
Abbreviation: CI, confidence interval. Effect is the change in dosage for HLA-DRB1*03:01 between positive and negative for specified phenotype. 
(A) Results for healthy control/anti-Ro-negative/anti-Ro-positive. (B) Results healthy control/anti-La-negative/anti-La-positive.
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